More on KYMR

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (9.0 Score)
- Holders

Upcoming Events

- Earnings (7/31/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Kymera Therapeutics (NQ:KYMR)
Delayed: 85.43 -0.78 (0.9%)
Prev. Close $86.21  
Open$86.27 
52 Wk High$ 
52 Wk Low$ 
Day High$88.59 
Day Low$84.84 
P/E N/A  
EPS$ 
Volume241,539 

Friends, Peers and Foes (?): GILD, PTCT, SNY, ASND, APOG (more...)

Jun 12, 2026 07:00 AM Kymera presents phase 1 data for KT-621 in healthy Japanese adults
Jun 12, 2026 07:00 AM Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Jun 9, 2026 07:00 AM Kymera begins phase 1 trial of KT-485, receives $20M from Sanofi
Jun 9, 2026 07:00 AM Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
Jun 8, 2026 04:05 PM Form 8-K Kymera Therapeutics, For: Jun 05
Jun 8, 2026 04:01 PM Kymera Therapeutics names Penny Carlson development operations head
Jun 8, 2026 04:01 PM Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
Jun 8, 2026 01:05 PM Kymera Therapeutics (KYMR) PT Raised to $97 at Brookline Capital Markets
Jun 8, 2026 07:00 AM Kymera presents preclinical lupus data for oral IRF5 degrader KT-579
Jun 8, 2026 07:00 AM Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
View All Articles

Entities mentioned with KYMR

View All Entities